Montana's SB535, signed into law in May 2025, authorizes investigational drugs that have cleared Phase I trials to be prescribed and sold, bypassing the traditional FDA approval pathway. The law makes Montana the first state to license experimental treatment centers, positioning it as a highly attractive location for biopharma and life sciences.
Tap to vote and see what everyone thinks.
Summary by ByteBrief
UK approves Novo weight-loss pill to edge open European market